COPD Patients Clinical Trial
Official title:
Non-Invasive Markers for Chronic Obstructive Pulmonary Disease (COPD)
NCT number | NCT00180622 |
Other study ID # | SD-000-068 |
Secondary ID | |
Status | Withdrawn |
Phase | |
First received | |
Last updated | |
Start date | July 1, 2001 |
Est. completion date | July 1, 2002 |
Verified date | July 2019 |
Source | Imperial College London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary aim of this study is to exploit a difference between COPD patients, chronic smokers without COPD and healthy non-smoking subjects. This will help to assess the utility of inflammatory and oxidative markers in exhaled air and sputum and to compare them with the lung function, clinical parameters and computerised tomography (CT).
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | July 1, 2002 |
Est. primary completion date | July 1, 2002 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 30 Years to 75 Years |
Eligibility |
Inclusion Criteria: Healthy non-smokers - FEV1 >80% predicted - FEV1 reversibility of <10% after inhaled (beta2-agonists Current smokers - FEV1 no less than 80% predicted - FEV1 reversibility of <10% after inhaled (beta2-agonists - Smoking history of > 10 pack-years Moderate COPD - FEV1 40-59% predicted - FEV1 reversibility of <10% after inhaled (beta2-agonists - Smoking history of > 10 pack-years** Severe COPD - FEV1 <40% predicted - FEV1 reversibility of <10% after inhaled (beta2-agonists - Smoking history of > 10 pack-years Exclusion Criteria: - FEV1 increases by 200 ml and 15% of the baseline value after inhaled (beta2-agonists - Asthma - unstable disease (FEV1 <35% predicted) and/or current, or within the last 4 weeks, respiratory tract infection. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital | London |
Lead Sponsor | Collaborator |
---|---|
Imperial College London | AstraZeneca |
United Kingdom,
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05980611 -
Nasal IL 1 Beta ,IL 3 Level and Their Effects in COPD Patients
|
||
Recruiting |
NCT00949195 -
Pulmonary Arterial Pressure Response During Exercise
|
N/A | |
Completed |
NCT06128902 -
The Effect of Home-Based Monitoring, Exercise Training
|
N/A | |
Completed |
NCT01475812 -
Daily Activities Are Sufficient to Induce Dynamic Pulmonary Hyperinflation and Dyspnea in Chronic Obstructive Pulmonary Disease Patients
|
N/A | |
Completed |
NCT02157935 -
Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
|
Phase 3 | |
Completed |
NCT01183052 -
Mitochondrial Dysfunction and Oxidative Stress in Chronic Obstructive Pulmonary Disease (COPD) Patients
|
N/A | |
Completed |
NCT04869033 -
Effects of Farinelli's Breathing Exercise in COPD Patients
|
N/A | |
Completed |
NCT02099279 -
Prognostic Value Cardiac Dysfunction Assessed by Bedside Echocardiography in Critically Ill COPD Patients Requiring Mechanical Ventilation
|
N/A | |
Withdrawn |
NCT00361426 -
EarlySense Monitoring Device Evaluation on COPD, CHF and Pneumonia Patients
|
N/A | |
Recruiting |
NCT03774238 -
Determinants of the Vascular Response to Training in Chronic Obstructive Pulmonary Disease (COPD) Patients
|
N/A | |
Enrolling by invitation |
NCT03851991 -
The Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD.
|
Phase 4 |